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Interactions between the insect immune system and RNA viruses have been extensively studied in 17 
Drosophila, where RNA interference, NF-κB and JAK-STAT pathways underlie antiviral immunity. In 18 
response to RNA interference, insect viruses have convergently evolved suppressors of this pathway 19 
that act by diverse mechanisms to permit viral replication. However, interactions between the insect 20 
immune system and DNA viruses have received less attention, primarily because few Drosophila-21 
infecting DNA virus isolates are available. Here, we use a recently-isolated DNA virus of Drosophila 22 
melanogaster, Kallithea virus (family Nudiviridae), to probe known antiviral immune responses and 23 
virus evasion tactics in the context of DNA virus infection. We find that fly mutants for RNA 24 
interference and Immune deficiency (Imd), but not Toll, pathways are more susceptible to Kallithea 25 
virus infection. We identify the Kallithea virus-encoded protein gp83 as a potent inhibitor of Toll 26 
signalling, suggesting that Toll mediates antiviral defense against Kallithea virus infection, but that it 27 
is suppressed by the virus. We find that Kallithea virus gp83 inhibits Toll signalling through the 28 
regulation of NF-κB transcription factors. Furthermore, we find that gp83 of the closely related 29 
Drosophila innubila nudivirus (DiNV) suppresses D. melanogaster Toll signalling, suggesting an 30 
evolutionary conserved function of Toll in defense against DNA viruses. Together, these results 31 
provide a broad description of known antiviral pathways in the context of DNA virus infection and 32 
identify the first Toll pathway inhibitor in a Drosophila virus, extending the known diversity of insect 33 
virus-encoded immune inhibitors. 34 
 35 
Importance 36 
Co-evolution of multicellular organisms and their natural viruses may lead to an intricate relationship 37 
in which host survival requires effective immunity, and virus survival depends on evasion of such 38 
responses.  Insect antiviral immunity, and reciprocal virus immune suppression tactics, have been 39 
well-studied in Drosophila melanogaster, primarily during RNA, but not DNA, virus infection. 40 
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Therefore, we describe interactions between a recently-isolated Drosophila DNA virus (Kallithea 41 
virus - KV) and immune processes known to control RNA viruses, such as RNAi and Imd pathways. 42 
We find that KV suppresses the Toll pathway, and identify gp83 as a KV-encoded protein that 43 
underlies this suppression. This immunosuppressive ability is conserved in another nudivirus, 44 
suggesting the Toll pathway has conserved antiviral activity against DNA nudiviruses, which have 45 
evolved suppressors in response. Together, these results indicate that DNA viruses induce and 46 
suppress NF-κB responses, and advance the application of KV as a model to study insect immunity. 47 




Innate antiviral immunity in insects has been best studied in response to RNA virus infections of 50 
Drosophila melanogaster. Antiviral immune mechanisms that target RNA viruses include RNA-51 
mediated defences such as RNA interference (RNAi) and RNA decay pathways, cellular defences such 52 
as apoptosis, phagocytosis, and autophagy, and other effectors of resistance and tolerance that are 53 
transcriptionally induced following infection. The latter are primarily mediated by Janus 54 
kinase/signal transducers and activators of transcription (JAK-STAT) and Nuclear factor κB (NF-κB) 55 
pathways (reviewed in (1–5).  56 
The insect response to DNA viruses is less well studied, but RNAi and apoptosis have demonstrated 57 
antiviral activity (6–8) and the JAK-STAT pathway is active during infection, possibly mediating a 58 
tolerance response (9). Baculovirus, nudivirus, and iridovirus infections of Drosophila all give rise to 59 
virus-derived small interfering RNA (vsiRNAs), which regulate DNA virus gene expression (7, 8, 10, 60 
11) and mutants for RNAi effectors Dicer-2 (Dcr-2) and Argonaute-2 (AGO2) are hypersensitive to 61 
Invertebrate iridescent virus 6 (IIV6; an iridovirus) infection. This suggests that RNAi is also an 62 
important defence against DNA viruses, and IIV6 correspondingly encodes a suppressor of RNAi (7, 63 
12). Virus-encoded suppressors of apoptosis are also widespread in DNA viruses, acting through 64 
binding and inhibition of cellular caspases (e.g. p35), or stabilization of cellular inhibitors of 65 
apoptosis (e.g. IAP gene family; (13–15)). In contrast, the contribution of transcriptional responses, 66 
such as the NF-κB pathways, to DNA viruses has not yet been elucidated. 67 
There are two NF-κB pathways in Drosophila: Toll and Imd, which primarily function in antibacterial 68 
(Toll: gram-positive, Imd: gram-negative) and antifungal (Toll) defense, although both provide 69 
protection against some RNA viruses (reviewed in (1, 4, 5, 16, 17)). Toll and Imd pathways are 70 
activated following recognition of a pathogen-associated molecular patterns (PAMP; e.g. bacterial 71 
peptidoglycan), leading to the phosphorylation and degradation of the inhibitor of kappa B (IκB; 72 
encoded by cactus for Toll signalling, and by the relish C-terminus in Imd signalling) (reviewed in (16, 73 
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17). Under non-signalling conditions, IκB sequesters NF-κB transcription factors in the cytoplasm. 74 
These transcription factors are encoded by dorsal (dl) and Dorsal immune-related factor (Dif) in Toll 75 
signalling, and Relish (Rel) in Imd signalling, and all translocate to the nucleus to induce gene 76 
expression following IκB degradation (reviewed in (16, 17). Although the mechanism by which Toll 77 
and Imd recognise RNA viruses is unclear, both are active and provide immunity against some viral 78 
infections in insects, most likely through induction of antiviral effector responses. For example, Toll 79 
is broadly antiviral against RNA viruses such as Drosophila C virus, Nora virus, and Flock House virus 80 
in Drosophila during orally acquired, but not systemic infections, and in Aedes mosquitoes against 81 
dengue virus (18–21). Additionally, Imd is antiviral against a subset of viruses in Drosophila, such as 82 
Cricket Paralysis virus, Drosophila C virus, and Sindbis virus and in Aedes cell culture against the 83 
alphaviruses Semliki Forest virus and O’nyong’nyong virus (22–26).  84 
Although the effect of NF-κB signalling on DNA virus infection in insects has not been directly tested, 85 
polydnaviruses, ascoviruses, baculoviruses, and entomopoxviruses have acquired suppressors of NF-86 
κB signalling by horizontal gene transfer, providing indirect evidence for anti-DNA virus activity of 87 
NF-κB pathways (27, 28). First, a ‘polydnavirus’ encoded in the genome of the Braconid parasitoid 88 
wasp Microplitis demolitor has acquired homologs of IκB, some of which inhibit Dif and Rel by direct 89 
binding (27). However, this is a domesticated endogenous viral element that forms viral particles 90 
injected into the parasitoid’s host, and as these IκB homologues are not found in related nudiviruses, 91 
baculoviruses, or hytrosaviruses, it seems likely that they were acquired to inhibit anti-parasitoid 92 
immune responses in the host of the parasitoid wasp, rather than the antiviral immune response of 93 
the wasp itself (29, 30). Second, homologs of diedel, which encode a cytokine that inhibits apoptosis 94 
and the Imd pathway in Drosophila, are similarly found in ascoviruses, baculoviruses, and 95 
entomopoxviruses, likely through independent horizontal transfer from arthropod hosts (28). Virus-96 
encoded diedel phenocopies fly-encoded diedel, suggesting that viral diedel has retained an Imd-97 
suppressive function, and that the Imd pathway likely interacts with these DNA viruses (28, 31). 98 
However, it is still unclear whether antiviral Toll signalling is targeted by insect virus-encoded 99 
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immune suppressors, and whether these hijacked host pathway inhibitors represent a subset of a 100 
greater diversity of NF-κB immune inhibitors or reflect evasion of virus-specific immune 101 
mechanisms. 102 
The recent isolation of Kallithea virus (KV; (11, 32), a nudivirus that naturally infects Drosophila 103 
melanogaster at high prevalence in the wild, provides a tractable system to study host-DNA virus 104 
interactions and to identify immune evasion strategies in DNA viruses. Nudiviruses are large dsDNA 105 
viruses (100-200 kilobases, encoding roughly 100-150 genes) that most often infect the arthropod 106 
midgut and fat body and are transmitted faecal-orally (33–39). Because some virus-encoded immune 107 
suppressors have been found to be highly host-specific, the use of native host-virus pairs is vital to 108 
our understanding of viral immune evasion (e.g. (40–45). Here, we use this system to analyze the 109 
interaction between antiviral immune pathways and a DNA virus in Drosophila. Using mutant fly 110 
lines, we find that the RNAi and Imd pathways mediate antiviral protection against KV in vivo, but 111 
that abrogation of Toll signalling has no effect on virus replication. Through re-analysis of previous 112 
RNA-sequencing data, we observe a broad downregulation of NF-κB responsive antimicrobial 113 
peptides following KV infection and perform a small-scale screen for KV-encoded immune inhibitors. 114 
We identify viral protein gp83 as having a complex interaction with NF-κB signalling, leading to 115 
induction of Imd signalling but potent suppression of Toll signalling. This suppression acts directly 116 
through, or downstream of, NF-κB transcription factors. Finally, through analysis of the related 117 
Drosophila innubila nudivirus (DiNV) gp83 ortholog, we show that the immunosuppressive activity of 118 
gp83 against D. melanogaster NF-κB signalling is conserved. 119 
 120 
Materials and Methods 121 
Fly strains, virus growth, and mortality experiments 122 
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All fly lines were maintained and crossed on standard cornmeal medium at 25 °C. Viral titre and 123 
mortality were measured following KV infection in two control lines (w1118 and Oregon R) and in 124 
mutant lines compromised in the following immune signalling pathways: RNAi (Dcr-2L811fsX (46) and 125 
AGO2414 (47)), Toll (spz4 (48), dl1 (49), and pll2/pll21 trans-heterozygotes (51, 52)), and Imd (rele20 (53) 126 
and imd10191 (54)).  127 
For mortality assays, 100 female flies of each genotype were injected with 50 nL of either KV 128 
suspension (105 ID50, as described in (32)) or chloroform-treated KV suspension (which inactivates KV 129 
through the destruction of the membrane, (32)). For chloroform treatment, the KV suspension was 130 
mixed with an equal volume of chloroform, vortexed for 30 seconds, centrifuged for 5 minutes at 131 
6000xg, and the aqueous phase was taken for downstream experiments. Injected flies were 132 
transferred to sucrose agar vials in groups of 10, and the number of surviving flies was recorded 133 
daily. While maintenance of flies on a protein-free diet likely affects some aspects of the immune 134 
response, we have assumed this is similarly tolerated across the fly lines used. Each group of flies 135 
was transferred to fresh food each week. Per-day mortality was analysed as a binomial response 136 
variable with the Bayesian generalised linear mixed modelling R package, MCMCglmm (55), with 137 
days post-inoculation (dpi), dpi2 (to allow for non-linear changes in mortality), and genotype as fixed 138 
effects, and vial as a random effect, as described previously (32). All confidence intervals are 139 
reported as 95% highest posterior density (HPD) intervals. All code used to fit the models described 140 
in this study, and associated data, are available on Figshare (doi: 10.6084/m9.figshare.c.4151009). 141 
Viral titre was measured in each line after intra-abdominal injection of 50 nL of KV suspension. 142 
Infected female flies of each line (n=50) were transferred to 10 sucrose agar vials in groups of 5, and 143 
5 vials of each genotype were homogenised in Trizol (Invitrogen) at 5 and 10 dpi. For RNAi mutants, 144 
flies were also assayed at 3 dpi. DNA was extracted by phenol-chloroform precipitation and viral titre 145 
estimated by quantitative PCR relative to host genomic DNA, using previously described primers 146 
(rpl32; (32)). Log-transformed viral titre was analysed as a Gaussian response variable using 147 
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MCMCglmm (55), with genotype, dpi, and genotype-by-dpi interactions as fixed effects. Titre in RNAi 148 
and NF-κB mutants were assayed in separate experiments, and therefore analysed independently. A 149 
statistical approach was used to account for the impact of differing genetic backgrounds between 150 
mutant lines, using the range of KV titres seen previously across 120 different natural genetic 151 
backgrounds from the Drosophila Genetic Reference Panel (32). Specifically, considering w1118 and 152 
Oregon R as controls and mutants of each pathway as the ‘experimental’ group, a null distribution of 153 
effect sizes expected only from differences in genetic background was created by randomly choosing 154 
two DGRP lines to serve as controls and additional DGRP lines reflecting the mutant lines used in 155 
each pathway. For each null draw, the same model was fitted as described above, the absolute value 156 
of the effect size was recorded, and this was repeated 1000 times to obtain a distribution. If the 157 
average effect size associated with mutants in a pathway was greater than the highest 5% of effect 158 
sizes, we concluded that the observed differences in KV titre were due to mutations in the tested 159 
pathway. 160 
Cell culture and virus propagation 161 
S2 cells (Invitrogen) were cultured at 25 °C in Schneider’s Drosophila Medium with 10% heat-162 
inactivated fetal bovine serum and 50 U/mL penicillin and 50 ug/mL streptomycin (Life 163 
technologies). KV was purified from flies 10 days after initial infection as previously described (32). 164 
Briefly, KV was injected into 2000 Oregon R adult flies, which were incubated at 25 °C for 10 days, 165 
homogenised in 5 mL 10 mM Tris-HCl, filtered through cheese cloth, centrifuged twice for 10 166 
minutes at 6000xg, filtered through a 0.22 µm polyvinylidene fluoride syringe filter, and subject to 167 
gradient centrifugation in an iodixanol (Optiprep) gradient (32). KV-positive fractions of the gradient, 168 
as assessed by qPCR, were kept as the KV isolate. To measure the effects of KV on cell size and 169 
number, 5x104 S2 cells were seeded in 96-well plates, followed by the immediate addition of 5 μL of 170 
either KV suspension (103 ID50) or chloroform-treated KV. Cells were split once 7 dpi, and cell size 171 
and number was measured using FIJI 10 dpi (56). 172 
9 
 
Cloning  173 
We selected 9 KV genes identified as highly expressed at three dpi (32) to screen for KV-encoded 174 
immune suppressors. These were gp23, gp43, gp83, ACH96233.1-like, ACH96143.1-like, putative 175 
protein 1, putative protein 12, putative protein 15, putative serine protease (corresponding to 176 
GenBank accession numbers AKH40365.1, AKH40394.1, AKH40369.1, AKH40392.1, AKH40340.1, 177 
AQN78560.1, AKH40392.1, AKH40404.1, and AQN78556.1). Each KV gene was amplified using the 178 
Qiagen Long Range PCR kit as per the manufacturer’s instructions, with primers that introduced 179 
restriction sites and the Drosophila Kozak sequence (restriction enzymes and primers used in (Table 180 
1), and cloned into a pAc5.1 vector (Invitrogen) with a C-terminal V5-His tag. The KV gene gp83 was 181 
also cloned into pAc5.1 vector with GFP instead of V5-His to introduce a C-terminal GFP tag. Deletion 182 
constructs for gp83 were created by separately amplifying 2 segments of gp83 with primers that 183 
span the desired deletion and performing a second PCR reaction with these segments as a template, 184 
and the forward and reverse primers from the 5’ and 3’ segments, respectively (Table 1; gp83Δ1: 185 
CGLIECSELLRDRLCSKL deletion; gp83Δ2: WSDRLNLI deletion). The resulting amplicons with deletions 186 
were cloned as described above. The gp83 gene from DiNV (35, 57) was also cloned as above (Table 187 
1).  188 
Additionally, Toll pathway components pll, tube, cact, Dif, and dl were cloned into the pAc5.1 vector, 189 
as described above (Table 1). Other Toll and Imd pathway constructs have been described before: 190 
pAc5.1-TollLRR (58), pAc5.1-dl-GFP (59), pMT-PGRP-LCx (60), pAc5.1-rel-GFP (61), and the firefly 191 
luciferase (FLuc) reporter plasmids with promoter sequences from Drosomycin (Drs), Diptericin (Dpt), 192 
and Attacin-A (Att-A) (58) or with 10X STAT binding sites (62).  193 
Transfection and RNAi Knockdown in S2 cells 194 
S2 cells were transfected using Effectene transfection reagent, as per the manufacturer’s 195 
instructions. Double-stranded RNA (dsRNA) was synthesized against cactus, gp83, FLuc, renilla 196 
luciferase (RLuc), and GFP for RNAi-mediated knockdown. Primers with flanking T7 sequences were 197 
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used to amplify regions of each gene (Table 1) and dsRNA was synthesized from the resulting PCR 198 
products with T7 RNA polymerase and purified using GenElute Total RNA mini kit (Qiagen) (63). 199 
Immune suppression assays 200 
The 9 cloned KV genes were tested for their ability to suppress RNAi, JAK-STAT, Toll, or Imd activity. 201 
RNAi suppression assays were performed as described previously (63). Briefly, 5x104 S2 cells were 202 
seeded in a 96-well plate and 24 hours later transfected with 33 ng of pMT-FLuc, 33 ng pMT-Rluc, 203 
and 33 ng of either pAc5.1 empty vector or the pAc5.1 expression plasmid encoding a KV gene. Two 204 
days later, 400 ng of either GFP or FLuc dsRNA was added to each well, and CuSO4 was added 8 205 
hours later to a final concentration of 500 µM to induce expression of the luciferase reporters. RLuc 206 
and FLuc luciferase activity were measured using the Dual Luciferase Assay Kit (Promega). 207 
For JAK-STAT immunosuppression assays, 5x104 S2 cells were seeded in a 96-well plate and 208 
transfected 24 hours later with 30 ng of 10XSTAT-FLuc, 20 ng pAc5.1-Rluc, and 50 ng of either pAc5.1 209 
empty vector or the pAc5.1 expression plasmid encoding a KV gene. Luciferase activity was 210 
measured at 48 hours following transfection. 211 
For NF-κB immunosuppression assays, a plasmid encoding the Imd receptor PGRP-LC (isoform x; 212 
pMT-PGRP-LCx) (60, 64) or a constitutively active Toll construct lacking the extracellular leucine-rich 213 
repeat domain, pAc5.1-TollLRR (58) was transfected alongside each KV gene, and a NF-κB-responsive 214 
FLuc reporter containing either the Dpt (Imd) or Drs (Toll) promoter sequence (58). For Toll immune 215 
suppression assays, 5x104 S2 cells were seeded in 96-well plates and 24 hours later transfected with 216 
50 ng of either empty pAc5.1 vector or a pAc5.1 KV gene expression construct, 20 ng of either 217 
pAc5.1 or pAc5.1-TollLRR, 10 ng of Drs-FLuc, and 10 ng pAc5.1-Rluc. Imd immune suppression assays 218 
were performed in the same manner, except that pMT, pMT-PGRP-LCx, and Dpt-FLuc were 219 
substituted for pAc5.1, pAc5.1-TollLRR, and Drs-FLuc, respectively, and CuSO4 was added immediately 220 
following transfection. Analogous experiments were performed using pAc5.1-dl, pAc5.1-Dif, and 221 
pAc5.1-pll instead of pAc5.1-TollLRR, or by transfecting 5 ng of cact dsRNA. In the latter case, 70 ng of 222 
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KV gene expression construct was transfected instead of 50 ng. RLuc and FLuc activity were assayed 223 
48 hours after transfection.  224 
Immunosuppression assays were also performed using KV-infected cells. 5x104 cells were seeded in 225 
96-well plates, followed by the immediate addition of 5 μL of either KV suspension (103 ID50) or 226 
chloroform-treated KV, and transfected the next day. For RNAi suppression assays with KV, 50 ng 227 
pMT-RLuc, 50 ng pMT-FLuc (63), and 5 ng of either GFP or GL3 dsRNA were transfected 2 dpi and 228 
CuSO4 added 8 hours later. To measure JAK-STAT activity following KV infection, 70 ng of 10XSTAT-229 
FLuc and 30 ng pAc5.1-Rluc (65) were transfected. For Toll suppression assays, 70 ng of either pAc5.1 230 
or pAc5.1-TollLRR, 20 ng of Drs-FLuc, and 10 ng pAc-RLuc were transfected. Finally, to measure Imd 231 
activity following KV infection, 70 ng of either pMT or pMT-PGRP-LCx, 20 ng of Dpt-FLuc, and 10 ng 232 
pAc-RLuc were transfected, and CuSO4 was added immediately following transfection. Luciferase 233 
activity was measured at 4 dpi. 234 
The R package MCMglmm was used to determine significance in immune suppression assays, with 235 
the RLuc-normalised FLuc values as a Gaussian response variable. In the original screen for immune 236 
suppressors, any experimental induction of an immune pathway was treated as a fixed effect (e.g. 237 
addition of dsRNA against FLuc in the RNAi suppression assay, PGRP-LC overexpression in the Imd 238 
suppression assay, and TollLRR transgene expression in the Toll suppression assay), each KV gene was 239 
treated as a random effect, and the interaction between KV gene and the induced experimental 240 
change to signalling output was treated as a random effect. In subsequent NF-κB suppression 241 
experiments, where the only tested KV gene was gp83, gp83 and the interaction between gp83 and 242 
overexpression of NF-κB receptors were treated as fixed effects. Likewise, when immune 243 
suppression experiments were carried out with KV-infected cells instead of cells expressing 244 
individual KV transgenes, KV infection status, the induction of an immune pathway, and the 245 
interaction between these were treated as fixed effects.  246 
Immunoprecipitation and western blotting 247 
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To test whether gp83 directly interacted with dl, 2x106 S2 cells were seeded in 6-well plates and 248 
transfected with 150 ng of either pAc5.1 empty vector, pAc5.1 encoding V5-tagged gp83, or V5-249 
tagged cact alongside 150 ng of the expression plasmid (pAc5.1) encoding GFP or GFP-tagged dl. Two 250 
days post-transfection, two wells per treatment were resuspended in lysis buffer (0.1% NP-40, 30 251 
mM Hepes-KOH, 150 mM NaCl, 2mM MgOAc) supplemented with cOmplete protease inhibitor 252 
cocktail (Roche) and 5 mM DTT, and disrupted 30 times through a 25-gauge needle. After 10 minutes 253 
incubation on ice, cell debris was pelleted by centrifuging at 16,000xg for 30 minutes and 254 
supernatant was either stored as an input control or collected and incubated for 5 hours at 4 °C with 255 
magnetic control beads. Binding control beads were removed and the resulting supernatant was 256 
incubated with GFP-trap magnetic beads (Chromotek) overnight at 4 °C. Beads were washed 3 times 257 
in lysis buffer and 3 times in 25 mM Tris-HCl, 150 mM NaCl solution, and protein complexes eluted 258 
by boiling 10 minutes at 95 °C in Laemmli buffer. 259 
Whole cellular protein extracts were prepared by heating S2 cells for 10 min at 95 °C in Laemmli 260 
buffer. Whole cellular extracts or immunoprecipitated proteins were separated on a 12% SDS-PAGE 261 
gel and transferred to a nitrocellulose membrane. Non-specific binding was blocked with blocking 262 
solution (phosphate buffered saline with 0.1% Triton-X (PBT) and 5% dry milk). Proteins of interest 263 
were probed with primary antibody diluted in blocking solution overnight at 4 °C, and visualized with 264 
an hour incubation of secondary antibody in blocking solution. Membranes were washed 3 times in 265 
PBT before and after each step. The following antibodies were used: mouse anti-dl (1:100 dilution, 266 
Developmental Studies Hybridoma Bank), mouse anti-V5 (1:1000 dilution, Invitrogen), rat anti-tub-α 267 
(1:1000 dilution, SanBio), and rabbit anti-GFP (1:1500 dilution, abcam ab6556) as primary 268 
antibodies, and goat anti-mouse IR-Dye 680 (1:15,000 dilution, LI-COR), goat anti-rat IR-Dye 800 269 
(1:15,000 dilution, LI-COR), goat anti-rabbit IR-Dye 800 (1:15,000, LI-COR). An Odyssey Infrared 270 
Imager (LI-COR) was used to image blots. 271 
Mass spectrometry 272 
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106 S2 cells were co-transfected with pCoBLAST and pAc5.1-gp83GFP plasmid at a 1:19 ratio (125 ng 273 
and 2.38 μg, respectively). Medium was replaced 3 hours post-transfection, and again at 48 hours 274 
post-transfection with medium supplemented with blasticidin (20 μg/mL). Another 48 hours later, 275 
cells were refreshed with medium containing 4 μg/mL blasticidin, which was thereafter replaced 276 
every 3-4 days with medium containing 4 μg/mL blasticidin, resulting in a polyclonal cell line.  277 
For mass spectrometry, wild-type S2 cells or S2 cells stably expressing GP83GFP were lysed in 50mM 278 
Tris-HCl (pH 7.8), 150mM NaCl, 1% NP-40, 0.5mM DTT, 10% glycerol, and protease inhibitor cocktail 279 
(Roche). Approximately 4 mg of protein lysate was subjected to GFP-affinity purification using 7.5 μL 280 
GFP-trap beads (Chromotek) for approximately 1.5 hours at 4 °C. Beads were washed twice in lysis 281 
buffer, twice in PBS containing 1% NP-40, and three times in PBS, followed by on-bead trypsin 282 
digestion as described previously (66). Afterwards, tryptic peptides were acidified and desalted using 283 
Stagetips, eluted, and brought onto an EASY-nLC 1000 Liquid Chromatograph (Thermo Scientific). 284 
Mass spectra were recorded on a QExactive mass spectrometer (Thermo Scientific) and MS and MS2 285 
data were recorded using TOP10 data-dependent acquisition. Maxquant (v1.5.1.0) was used to 286 
analyse raw data, using recommended settings (67). LFQ, IBAQ, and match between runs were 287 
enabled. The peptides were mapped to D. melanogaster proteins (UniProt June 2017) and 288 
contaminants and reverse hits were filtered with Perseus (v1.3.0.4) (68). Missing values were 289 
imputed, assuming a normal distribution, and significance determined by a t-test on log-transformed 290 
LFQ-values between wild-type and gp83-expressing S2 cells.  291 
Immunofluorescence microscopy  292 
5x105 S2 cells were seeded in 12-well plates with glass coverslips in each well. Cells were transfected 293 
with 100 ng of pAc5.1 or pAc5.1-gp83-V5 and 100 ng of pAc5.1-dl-GFP. Two days after transfection, 294 
cells were fixed with 4% paraformaldehyde, washed twice in PBS, once with PBT, and blocked with 295 
PBT with 10% goat serum. Cells were stained by incubation with mouse anti-V5 (1:400, Invitrogen) 296 
for one hour, followed by fluorophore-containing goat anti-mouse secondary antibody (1:400, 297 
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AlexaFluor) with 10 ug/mL Hoechst for one hour. Finally, cells were washed twice in PBT and twice in 298 
PBS, mounted on slides with Fluoromount-G (eBiosciences), and imaged with an Olympus FluoView 299 
FV1000. Fluorescence was measured in whole cells, or separately in the cytoplasm and nuclei by 300 
outlining the region of interest in Fiji (56) to calculate the mean fluorescence.  301 
Data availability 302 
All data presented in this manuscript, and associated code to fit statistical models, is provided via 303 
Figshare (doi: 10.6084/m9.figshare.c.4151009). 304 
 305 
Results and Discussion 306 
RNAi and Imd pathways are antiviral against KV in vivo 307 
The RNAi pathway provides antiviral activity against the DNA virus IIV6, and KV-derived vsiRNAs are 308 
produced upon infection of adult naturally-infected Drosophila (7, 11, 12). However, the 309 
contribution of Imd and Toll pathways to anti-DNA virus immunity have not been described. We 310 
used fly lines mutant for RNAi, Imd, and Toll pathway components to assess whether these 311 
pathways fulfil an antiviral function during KV infection. First, we infected mutants for RNAi genes 312 
Dcr-2 and AGO2 with KV, and measured viral titre and mortality following infection. Following KV 313 
infection, both Dcr-2 and AGO2 mutants exhibited significantly greater KV titres at 3 dpi, with KV 314 
titre 78-fold greater in Dcr-2 mutants (95% HPD intervals: 18-281 fold; MCMCp < 0.001) and 55-fold 315 
greater in AGO2 mutants (13-237 fold, MCMCp < 0.001; Figure 1A). However, the increased KV 316 
replication in RNAi mutants was not sustained at later infection timepoints. At 5 dpi, Dcr-2 mutants 317 
did not have significantly different KV titre from the controls (MCMCp = 0.22), but titres were still 318 
increased in AGO2 mutants, albeit to a lesser extent that at 3 dpi (12-fold increase; 2.5-43 fold, 319 
MCMCp < 0.001; Figure 1A). By 10 dpi, there was no significant difference between viral titre in 320 
control flies and either Dcr-2 mutants (MCMCp = 0.43) or AGO2 mutants (MCMCp = 0.7). Therefore, 321 
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either the antiviral effect of RNAi is short-lived (for example, a viral suppressor of RNAi may 322 
eventually be expressed in vivo), other immune pathways take over as the dominant antiviral force, 323 
or KV negatively regulates its own replication or depletes a resource. Nevertheless, despite the 324 
similar titres during late infection, there was still a significant increase in KV-induced mortality in 325 
Dcr-2 and AGO2 mutants, where 70% of control flies were alive at 19 dpi, compared to 25% in Dcr-2 326 
mutants (MCMCp = 0.014) and 38% in AGO2 mutants (MCMCp = 0.004, Figure 1B). Increased late life 327 
mortality in RNAi mutants could be due to early host damage or to increased expression of virulence 328 
factors throughout infection, expression of which could be regulated by RNAi, independent of KV 329 
titre (e.g. (10). These results extend the antiviral role of the RNAi pathway to KV infection. 330 
We next infected Imd and Toll pathway mutants with KV and assessed KV DNA levels by qPCR at 5 331 
and 10 dpi. We found that Imd pathway mutants had significantly greater viral titre as compared to 332 
two control lines, with imd mutants having 6-fold greater KV titre at 5 and 10 dpi (2.7-13.7 fold, 333 
MCMCp < 0.001), and Rel mutants having 8-fold greater viral titre at 5 and 10 dpi (3.1-15.9 fold, 334 
MCMCp < 0.001; Figure 1C). Because the Imd effect spans 5 and 10 dpi, and we have previously 335 
measured KV titre in 125 inbred lines of the Drosophila Genetic Reference Panel at 8 dpi (32, 69), we 336 
attempted to account for genetic background by comparing the average effect of Imd mutants to 337 
the distribution of effects consistent with natural variation in the genetic background. This analysis 338 
indicated that the increased titre observed in Imd mutants is unlikely to be due to genetic 339 
background (p = 0.01). We also infected flies mutant for the Toll pathway components spz, pll, and 340 
dl. Viral titre was unchanged in Toll pathway mutants compared to controls, and the pathway-level 341 
effect of Toll mutants was within the expected distribution of effects caused by differences in 342 
genetic background (p = 0.28). We conclude that the Imd pathway is antiviral against KV, but that 343 
abrogation of Toll function has no effect on KV growth. This could indicate that Toll is not antiviral 344 
against this DNA virus, or that the pathway is efficiently suppressed by virus infection. The latter is 345 
consistent with our observation that genes encoding antimicrobial peptides are generally 346 
downregulated in KV-infected flies compared to uninfected controls (Figure 1E), and we therefore 347 
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explored the capability of KV to suppress innate immune pathways using a cell culture model of 348 
immunosuppression. 349 
KV replicates efficiently in some Drosophila cell lines  350 
To establish a cell culture model for KV infection, we analyzed viral replication in five commonly-351 
used D. melanogaster cell lines. We found variation in the ability of KV to infect these cells, with 352 
efficient replication in several Drosophila S2 cell clones, including S2 (not shown), S2R+, and DL2 353 
cells, but no or inefficient replication in Kc167 and Dm-BG3-c2 cells (Figure 2A). In S2 cells, which we 354 
used for further analyses, KV was released into the medium at substantial levels starting from 3 dpi 355 
(Figure 2B). Therefore, in all subsequent experiments, we assayed cells at 4 dpi, assuming that a high 356 
proportion of cells would be infected at this timepoint. We did not observe any overt cytopathic 357 
effects of KV-infected cells within 14 days of infection. However, when KV-infected cells were 358 
passaged at 7 dpi, we observed larger (MCMCp < 0.001) and fewer (MCMCp < 0.001) cells, likely due 359 
to a decrease in cell proliferation (Figure 2C,D).  360 
KV leads to downregulation of JAK-STAT and Toll, and induction of Imd signalling in cell culture 361 
We used previously established luciferase reporter-based assays to describe the effect of KV 362 
infection on RNAi, JAK-STAT, Toll, and Imd pathways in cell culture. To determine if KV suppresses 363 
RNAi, we measured the RNAi silencing efficiency of cells inoculated with KV or chloroform-364 
inactivated KV (hereafter referred to as mock-treated) by co-transfecting an expression plasmid 365 
encoding FLuc with either GFP dsRNA or FLuc dsRNA. In both mock and KV-treated cells, FLuc dsRNA 366 
caused a 95% reduction in FLuc activity compared with GFP dsRNA treated cells, indicating that KV 367 
infection does not inhibit RNAi in cell culture (MCMCp = 0.9; Figure 3A). Many viruses studied in 368 
Drosophila encode a suppressor of RNAi (e.g. (12, 44, 65, 70–73), and therefore the absence of KV-369 
induced RNAi suppression is somewhat surprising. It is possible that KV-RNAi interactions are 370 
different in the cell types that are naturally infected by KV, and that our inability to observe RNAi 371 
suppressive activity is a limitation of the cell culture model. Alternatively, if KV transmission does not 372 
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occur until later stages of infection, there may be limited selective pressure to evade RNAi, as RNAi 373 
mutants and control flies have similar titres during late infection. 374 
The JAK-STAT pathway has an antiviral role during Drosophila C virus infection (74) and mediates 375 
tolerance to the DNA virus IIV6, evidenced by upregulation of vir-1 and Turandot (Tot) genes (9). 376 
However, previous in vivo transcriptional profiling did not identify strong differential expression of 377 
STAT-responsive genes following infection with KV (Figure 1E) (32). We assessed JAK-STAT activity in 378 
mock and KV-treated cells with a FLuc reporter driven by a promoter containing ten STAT binding 379 
sites (62). This reporter is endogenously active in S2 cells (62), but KV infection led to a 58% 380 
reduction in STAT-mediated FLuc activity (37-74%, MCMCp < 0.001; Figure 3C), indicating that JAK-381 
STAT is down-regulated or inhibited following KV infection. However, in addition to mediating a 382 
transcriptional immune response, the JAK-STAT pathway is involved in cell proliferation (75), which 383 
also decreases following KV infection in cell culture (Figure 2), making cause and effect difficult to 384 
distinguish. 385 
We next assayed the effect of KV on Toll and Imd signalling. However, these pathways are not 386 
constitutively active in S2 cells. To measure KV suppression of these pathways, we therefore co-387 
transfected TollLRR (a Toll receptor lacking the leucine-rich repeat extracellular domain) or PGRP-LC 388 
(an Imd pathway receptor) with Drs or Dpt luciferase reporters to artificially induce signalling of Toll 389 
and Imd pathways, respectively. Transfection of TollLRR increased Drs-Fluc by 243-fold (MCMCp < 390 
0.001), consistent with previous reports (58). However, KV infection reduced the maximum level of 391 
TollLRR-mediated Drs activity by 81% (38-93%, MCMCp < 0.001; Figure 3E), indicating KV can inhibit 392 
Toll signalling. Over-expression of PGRP-LC led to a 4-fold increase in Dpt-FLuc (3-5 fold, MCMCp < 393 
0.001). In contrast to the effect on Toll signalling, KV infection led to a 3.6-fold increase (2.6-4.8 fold, 394 
MCMCp < 0.001) in Dpt-FLuc, which additively increased when PGRP-LC overexpressing cells were 395 
infected with KV (17-fold increase compared to Imd-inactive, mock-treated cells; 12-23 fold, Figure 396 
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3G). These results suggest that KV infection in S2 cell culture leads to downregulation or suppression 397 
of Toll signalling but induction of Imd signalling. 398 
KV-encoded gp83 modifies NF-κB signalling during infection 399 
The immunosuppressive function of nudivirus genes has not previously been explored. Because we 400 
observe KV-mediated downregulation of NF-κB-regulated AMPs in vivo and downregulation of JAK-401 
STAT and Toll reporters in vitro, we wished to identify potential KV-encoded suppressors of 402 
canonical immune pathways. Therefore, we cloned 9 uncharacterized KV genes that are highly 403 
expressed at 3 dpi in adult flies (32) and performed immune suppression assays for RNAi, JAK-STAT, 404 
Toll, and Imd pathways. We were unable to identify KV-encoded suppressors of RNAi or JAK-STAT 405 
among these 9 genes, although we confirmed that Cricket Paralysis Virus protein 1A potently 406 
suppressed RNAi in these assays, as expected ((72); MCMCp = 0.006; Figure 3B,D). However, we 407 
found that gp83—a KV gene encoding no recognisable protein domains, named for its homology to 408 
the Gryllus bimaculatus nudivirus (GbNV) gp83 locus (76)—significantly reduced TollLRR-dependent 409 
Drs-FLuc expression (Figure 3F). In this experiment, TollLRR expression induced Drs-FLuc by 24-fold (8-410 
66 fold), but by only 1.9-fold (0.3-8 fold; MCMCp = 0.02) when gp83 was co-expressed. We further 411 
found that expression of gp83 caused a 5-fold (1.5-18 fold) increase in Imd-mediated Dpt-FLuc 412 
expression, with or without PGRP-LC overexpression (MCMCp = 0.008; Figure 3H).  413 
We next aimed to confirm that the interactions between the transfected KV gene gp83 and NF-κB 414 
pathways are representative of the function of gp83 during KV infection. Therefore, we silenced 415 
gp83 during KV infection using dsRNA, and measured associated changes in Toll, Imd, and JAK-STAT 416 
signalling. Co-transfection of gp83 with independent dsRNAs targeting gp83 completely reversed 417 
inhibition of Drs-FLuc compared with transfection of GFP dsRNA, indicating that these dsRNAs 418 
effectively silence gp83 (MCMCp < 0.001 for both dsRNAs; Figure 4D). As reported above (Figure 3E), 419 
KV infection had no effect on Drs-FLuc in the absence of TollLRR (MCMCp = 0.26), but inhibited TollLRR-420 
induced signalling (MCMCp < 0.001). Knockdown of gp83 during KV infection of TollLRR-expressing 421 
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cells led to increased Drs-FLuc (MCMCp < 0.001; orange bars in Figure 4A). Surprisingly, Drs-FLuc was 422 
also slightly increased in Toll-inactive cells upon KV infection and gp83 knockdown (MCMCp = 0.004; 423 
grey bars in Figure 4A). Likewise, knockdown of gp83 in KV-infected cells expressing PGRP-LC caused 424 
a decrease in Dpt-FLuc expression (MCMCp = 0.006; orange bars in Figure 4B), and this effect was 425 
also noticeable in controls that do not express PGRP-LC (MCMCp = 0.03; grey bars in Figure 4B). 426 
Consistent with a specific interaction with NF-κB signalling, gp83 knockdown had no effect on the 427 
ability of KV to downregulate JAK-STAT signalling in S2 cells (MCMCp = 0.63; Figure 4C). Together, 428 
these observations indicate that gp83 is responsible for Toll suppression and Imd activation during 429 
KV infection.  430 
The immunosuppressive function of gp83 on Toll signalling in vitro is consistent with the observed 431 
downregulation of AMPs following KV infection in vivo and substantiates the hypothesis that Toll is 432 
antiviral and suppressed during infection. However, the induction of antiviral Imd signalling by a 433 
single viral protein is unexpected, and it is unclear why KV has not evolved to avoid or suppress Imd 434 
activation as seen for other insect-infecting DNA viruses (28). Assuming that Imd activation is 435 
detrimental to virus transmission, this could indicate a trade-off between suppression of Toll and 436 
activation of Imd, or that gp83 is directly recognised by the fly immune system. Additionally, gp83-437 
mediated Imd activation in vitro is at odds with the observed broad downregulation of AMPs in vivo, 438 
which are controlled, in part, by Imd signalling. This could be explained by differences in the 439 
intracellular versus systemic effects of KV on Imd signalling, or tissue-specific responses to KV, either 440 
of which could mask an excitatory effect of gp83 on Imd in vivo. Because of these inconsistencies, we 441 
chose to focus specifically on the Toll immunosuppressive effect of gp83, because the in vitro data is 442 
consistent with observed AMP expression patterns in vivo. We conclude that KV-encoded gp83 is 443 
involved in mediating complex interactions with NF-κB signalling in vitro, including suppression of 444 
Toll signalling and induction of Imd signalling. 445 
Immune suppression by gp83 occurs downstream of Toll transcription factors 446 
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Previously described polydnavirus-encoded Toll pathway inhibitors imitate IκB, blocking the nuclear 447 
entry of NF-κB transcription factors (27). Although the precise mechanism of interaction between 448 
gp83 and Toll signalling is unknown, suppression of TollLRR-induced signalling indicates that gp83 449 
functions downstream of Toll, and interferes with intracellular Toll signalling. We therefore 450 
performed genetic interaction experiments between gp83 and downstream Toll components to 451 
narrow down the point in the Toll signalling pathway at which gp83 acts. As observed before with 452 
reporter assays, gp83 inhibited TollLRR-mediated signalling, now assessed by qRT-PCR of endogenous 453 
Drs expression (MCMCp < 0.001; Figure 5A).  Additionally, Drs-FLuc was greatly increased by 454 
overexpressing pll (240-fold [131-414] induction of Drs-FLuc), silencing cact (75-fold [33-161] 455 
induction of Drs-FLuc), overexpressing Dif (563-fold [317-1002] induction of Drs-FLuc; ), and 456 
overexpressing dl (459-fold [257-778] induction of Drs-FLuc; ). Co-expression of gp83 potently 457 
reduced Drs-FLuc in each of these scenarios (MCMCp < 0.001 for each) – pll/gp83 co-overexpression 458 
led to a 0.55-fold change in Drs-FLuc (0.31-0.99 fold), cactdsRNA/gp83 led to a 1.73-fold change in Drs-459 
FLuc (0.75-3.5 fold), Dif/gp83 led to a 0.86-fold change in Drs-FLuc (0.5-1.5 fold), and dl/gp83 led to a 460 
1.5-fold change in Drs-FLuc (0.9-2.5 fold) relative to baseline Drs-FLuc expression (Figure 5B-E). 461 
Additionally, V5 staining of V5 epitope-tagged gp83 revealed that gp83 is a nuclear protein (Figure 462 
5F). Together, these results indicate that gp83 either inhibits NF-κB transcription factors, or acts 463 
downstream of them to suppress Toll signalling in vitro. 464 
Virus-encoded inhibitors of NF-κB in mammals have been reported to operate by promoting 465 
degradation of NF-κB transcription factors, blocking NF-κB access to the nucleus, or interfering with 466 
transcriptional co-activators to evade the interferon response (reviewed in 77). In order to better 467 
define the mechanism of the immunosuppressive action of gp83, we searched for direct host 468 
interactions that may mediate Toll suppression. Because our genetic interaction experiments 469 
indicate that gp83 acts on or downstream of dl, we first tested for a physical interaction between dl 470 
and gp83 using co-immunoprecipitation and subsequent western blotting. Following 471 
immunoprecipitation of GFP-tagged dl, we were able to detect cact as an interacting positive 472 
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control, but we did not detect gp83 in GFP-dl immunoprecipitation (Figure 6C). Thus, to identify host 473 
interacting proteins of gp83 in an unbiased manner, we created an S2 cell line stably expressing GFP-474 
tagged gp83, immunoprecipitated gp83GFP, and performed quantitative mass spectrometry on 475 
interacting partners. We identified 19 D. melanogaster proteins, including 4 nuclear proteins 476 
(Nipped-B, Brf, Mlf, Ulp1), that were enriched in the gp83 immunoprecipitate (log2 fold enrichment > 477 
2.5; FDR < 0.1; Figure 6A). While we did not identify known downstream NF-κB pathway factors, the 478 
extracellular Toll ligand spz was enriched, despite the nuclear localization of gp83. However, peptide 479 
coverage of spz was poor and dsRNA knockdown of spz did not rescue the immunosuppressive 480 
effect of gp83, indicating that this interaction may not occur in live cells, or that it is not required for 481 
gp83 to inhibit Toll signalling (Figure 6B). Further, dsRNA-mediated knockdown of a subset of the 482 
enriched genes, including 3 of the 4 identified nuclear proteins, was unable to rescue the gp83 483 
immunosuppressive effect (Figure 6B), suggesting that gp83 may not form stable complexes with 484 
host proteins to interfere with NF-κB signalling.  485 
Although we did not detect a direct association between dl and gp83, we observed a reduction in dl 486 
protein levels upon gp83 overexpression that is not dependent on Toll signalling (Figure 7A). We 487 
quantified this effect by transfecting either GFP or GFP-tagged dl, in the absence or presence of 488 
gp83, and measuring fluorescence by confocal microscopy. We found that while gp83 caused a 53% 489 
reduction in GFP levels (42-62%, MCMCp < 0.001), possibly due to a dl binding site in the actin 5C 490 
promoter of this construct (78), gp83 caused a significantly greater reduction in dlGFP (73% reduction; 491 
66-78%, MCMCp < 0.001; Figure 7B,C). However, KV infection did not decrease dl protein levels, 492 
indicating that this may not be the primary mechanism by which KV inhibits Toll signalling (Figure 493 
7A). Instead, we hypothesize that gp83 interferes with the access of dl to either the nucleus or to NF-494 
κB binding sites, which indirectly affects dl localization and results in increased turnover. We prefer 495 
the latter explanation, that gp83 directly interferes with the Toll pathway transcriptional response, 496 
because overexpression of gp83 simultaneously induced the Dpt reporter (Figure 2H) and reduced 497 
dl-responsive promoters (Drs-FLuc and Act5C-GFP; Figure 3F, Figure 7B,C). These observations 498 
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implicate gp83 in regulating transcription at diverse loci responsive to both dl and Rel, and suggest 499 
an interaction between gp83 and NF-κB-responsive genes, possibly by directly interacting with DNA.   500 
Immunosuppressive function of gp83 depends on conserved residues and is conserved in other 501 
nudiviruses 502 
Conflict between the host immune system and virus-encoded immune inhibitors may result in an 503 
evolutionary arms race, leading to recurrent positive selection and eventual host specialization (e.g. 504 
(79–81). Consistent with this, some immune inhibitors are only effective against their native host 505 
species, thereby defining the viral host range (e.g. 40–45). We tested whether the 506 
immunosuppressive function of gp83 is conserved, and whether gp83 acts in a species-specific 507 
manner. The gp83 locus is absent from nudiviruses distantly related to KV, such as Heliothis zea 508 
nudivirus 1 (HzNV1), Tipula oleracea nudivirus (ToNV) and Peneaus monodon nudivirus (PmNV), but 509 
gp83 homologs are found in the more closely related GbNV, Nilaparvata lugens endogenous 510 
nudivirus (NlENV), Oryctes rhinoceros nudivirus (OrNV), Drosophila innubila nudivirus (DiNV), 511 
Tomelloso virus (TV), Mauternbach virus (MV), and Esparto virus (EV; Figure 8A). Although gp83 512 
lacks recognisable protein domains, several regions are strongly conserved among these nudiviruses, 513 
suggesting functional conservation (Figure 8B). To test whether gp83 function depends on these 514 
conserved domains, we made two gp83 deletion constructs (gp83Δ1 and gp83Δ2) that remove 515 
conserved regions of respectively 18 and 8 amino acids without substantially altering protein 516 
stability, and transfected these alongside TollLRR with the Drs-FLuc reporter. Although detectable by 517 
western blotting (Figure 8B), gp83Δ1 (MCMCp = 0.67) and gp83Δ2 (MCMCp = 0.79) were unable to 518 
inhibit Toll signalling, indicating that these conserved residues are important for the 519 
immunosuppressive function of gp83 (Figure 8C).  520 
To test whether gp83 function is conserved among viruses, we cloned gp83 from DiNV, which has 521 
not been found to be associated with D. melanogaster (11), and performed Toll immunosuppression 522 
assays. The gp83 homolog from DiNV was able to completely inhibit D. melanogaster Toll signalling 523 
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in S2 cells (MCMCp < 0.001), despite only 57% amino acid identity with KV gp83, demonstrating that 524 
the immunosuppressive function of gp83 is conserved in other nudiviruses and that it is not highly 525 
host-specific (Figure 8D). This observation suggests that the Toll-gp83 interaction may not be a 526 
hotspot of antagonistic ‘arms race’ coevolution and has not led to specialization of DiNV gp83 to the 527 
D. innubila immune system at the expense of its ability to function in D. melanogaster. This could be 528 
because gp83 has relatively few direct interactions with host proteins (Figure 6A), and may instead 529 
interact directly with transcription factor binding sites which are under high constraint, and 530 
therefore unable to evolve resistance to the immunosuppressive effect of gp83 (82). 531 
 532 
Conclusions 533 
In this study we investigated the role of known anti-RNA viral immune pathways in the context of 534 
DNA virus infection, including RNAi, JAK-STAT, Imd, and Toll pathways. Our data support an antiviral 535 
role for RNAi and Imd against KV, consistent with previously-described antiviral RNAi against IIV6 536 
and DNA virus-encoded suppressors of Imd (7, 8, 28). Furthermore, we identified gp83 as a KV-537 
encoded Toll suppressor that acts downstream of NF-κB transcription factor release of IκB in cell 538 
culture, suggesting that Toll signalling can be antiviral during DNA virus infection in insects. The 539 
immunosuppressive effect of gp83 is conserved in other nudiviruses, and has not evolved host-540 
specificity in DiNV, indicating that the Toll-gp83 interaction is unlikely to be a hotspot of reciprocal 541 
host-virus adaptation and that other KV genes may be more important in determining host range. 542 
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Figure legends 785 
 786 
Figure 1: RNAi and Imd pathways provide antiviral defense against Kallithea virus  787 
Mutants for RNAi (A,B) and NF-κB (C,D) pathways were assayed for viral titre (A,C,D) and mortality 788 
(B) following KV infection. OreR and w1118 flies were used as wild-type controls. Viral titre was 789 
measured by qPCR, relative to Rpl32 DNA, where each data point represents a vial of 5 flies, and 790 
coloured horizontal lines correspond to the mean titre and associated standard error (A,C,D). 791 
Horizontal dotted lines (A,C,D) represent the amount of virus injected. (B) RNAi mutants (AGO2 and 792 
Dcr2) and w1118 controls were injected with chloroform-treated KV (mock) or KV, and survival was 793 
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monitored each day. Each point is the mean number of surviving flies across 10 vials of 10 flies, with 794 
associated standard errors. (E) Log-transformed fold changes of presumed NF-κB-responsive genes 795 
(coloured red - Cecropins, Diptericins, Attacins, Metchnikowin, Drosomycins and Drosomycin-like 796 
genes, Bomamins (i.e. IM1, CG18107, IM2, IM3, CG15065, CG15068, CG43202, CG16836, CG5778, 797 
IM23, CG15067, CG5791), and other IM genes) and JAK-STAT-responsive genes (coloured blue - 798 
Socs36E, vir-1, and Turandot (Tot) family) following KV infection of OreR flies at 3 dpi, relative to 799 
uninfected controls (ERP023609; n = 5 libraries per treatment, with n=10 flies per library (32)). Error 800 
bars show standard errors of the mean. *p < 0.05; **p < 0.01; ***p < 0.001 (Statistical tests 801 




Figure 2: KV replicates in cell culture  804 
KV growth was assessed in various D. melanogaster cell lines by qPCR against the KV genome, 805 
relative to the fly gene Rpl32 (n=3 for each time point). (B) KV release from S2 cells into the culture 806 
medium was assessed by DNA extraction of 50 μL of culture medium and qPCR against the KV 807 
genome, plotted relative to the amount of KV in the medium directly following infection (i.e. zero 808 
time point is equal to 1). (C) Cell density (number of cells per approximately 100 μm2 in KV versus 809 
mock-treated cells) at 10 dpi (n=3). (D) Cell size of mock or KV-infected cells at 10 dpi. Each dot 810 
represents a single cell and the data distribution is presented as a violin plot. Error bars show 811 





Figure 3: Kallithea virus gp83 suppresses Toll and induces Imd signalling 815 
The ability of KV (4 dpi) and 9 highly expressed KV genes to inhibit RNAi (A,B), JAK-STAT (C,D), Toll 816 
(E,F), and Imd (G,H) pathways was assessed. For RNAi suppression assays (A,B), RNAi efficiency was 817 
assessed by transfecting S2 cells with expression plasmids expression FLuc and, as a normalization 818 
control RLuc, along with dsRNA targeting either FLuc or GDP. Data are expressed as fold silencing in 819 
cells treated with GFP dsRNA relative to those treated with FLuc dsRNA, normalised to 1 in mock-820 
infected cells. The CrPV suppressor of RNAi, protein 1A, was used as a positive control (data 821 
combined from 2 experiments).  For JAK-STAT suppression assays (C,D), S2 cells were transfected 822 
with a plasmid encoding FLuc under control of 10 STAT binding sites (10XSTAT-FLuc). In contrast to 823 
the JAK-STAT pathway, the Toll and Imd pathways are not endogenously active in S2 cells (grey bars 824 
in E, F, G, H), but can be activated by expression of TollLRR (orange bars in E, F) or PGRP-LC (orange 825 
bars in G, H). For Toll suppression assays (E,F), S2 cells were transfected with the Drs-FLuc reporter, 826 
encoding FLuc under control of a Drosomycin promoter, with either pAc5.1-TollLRR or an empty 827 
control plasmid (grey bars) For Imd suppression assays (G,H), S2 cells were transfected with the Dpt-828 
FLuc reporter, encoding FLuc under control of a Diptericin promoter, with either pMT (Empty) or 829 
pMT-PGRP-LC. All FLuc luciferase values were normalized to Renilla luciferase (RLuc) values, driven 830 
by a constitutively active Actin promoter from a co-transfected plasmid. PP=Putative Protein; 831 
SP=Serine Protease. Error bars show standard errors of the mean, calculated from 5 biological 832 
replicates for (A,C,E,G) and at least 3 biological replicates for (B,D,F,H). *p < 0.05; **p < 0.01; ***p < 833 




Figure 4: KV induction and suppression of NF-ΚB pathways is mediated by gp83 836 
The ability of KV to inhibit Toll (A), induce Imd (B), and inhibit JAK-STAT (C) was assessed during gp83 837 
knockdown, using two independent dsRNAs against gp83 (labelled ds-gp83200 and ds-gp83583). 838 
Drosomycin, diptericin, and 10X-STAT activity was measured as Drs-FLuc, Dpt-FLuc, and 10XSTAT-839 
FLuc expression, relative to RLuc expression as described in the legend to Figure 3. For each, data are 840 
presented as fold change in signalling following KV infection relative to mock infection (chloroform 841 
38 
 
treated KV) (4 dpi), where 1 (horizontal dotted line) represents no induction or suppression of the 842 
pathway by KV infection. (A) Fold change in Drs-FLuc expression following KV infection of S2 cells 843 
with (orange bars) or without (grey bars) activation of the pathway by TollLRR expression. (B) Fold 844 
change in Dpt-FLuc expression following KV infection of S2 cells with (orange bars) or without (grey 845 
bars) pathway activation by PGRP-LC expression. (C) Fold change in 10X-STAT FLuc expression 846 
following KV infection of S2 cells. (D) Efficiency of gp83 knockdown was assessed by co-transfection 847 
of an expression plasmid encoding gp83 with two independent dsRNAs against gp83 and Drs-FLuc 848 
reporter plasmids. Error bars show standard error of the mean (A-C: n = 5 biological replicates, D: n = 849 





Figure 5: gp83 inhibits Toll signalling downstream of Dif and dorsal 853 
(A) The ability to of gp83 to inhibit endogenous Drosomycin expression was assessed by transfection 854 
of S2 cells with pAc-gp83 or empty control plasmid, and the Toll pathway was activated by 855 
cotransfection of pAc-TollLRR or control plasmid. Drosomycin expression levels were measured 856 
relative to Rpl32 expression by qRT-PCR. (B-E) The Toll pathway was activated downstream of the 857 
Toll receptor by transfection of a plasmid encoding pll (B), knockdown of cactus with two 858 
40 
 
independent, non-overlapping dsRNAs (labelled ds-cact1 and ds-cact2) (C), and transfection of 859 
plasmids encoding the transcription factors dl and Dif (D,E). Activation of the pathway was assessed 860 
using  the Drs-FLuc reporter, relative to RLuc expression (orange bars in B-E; grey bars represent 861 
controls in which empty plasmids (B, D, E) or dsRNA targeting GFP (C) were transfected). Suppression 862 
of the Toll pathway at different stages by gp83 was assessed by co-transfection of pAc-gp83 or an 863 
empty control plasmid (B-E). (F) Representative confocal image of S2 cells expressing V5 epitope-864 
tagged gp83 stained with a V5 antibody (upper panel) and a merged image in which nuclei are 865 
stained with Hoechst (lower panel). Error bars show standard error of the mean (n = 5 biological 866 




Figure 6: Identification of host interactors of gp83  869 
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(A) Identification of gp83 interacting proteins in S2 cell lysates by label-free quantitative (LFQ) mass 870 
spectrometry. Permutation-based FDR-corrected t-tests were used to determine proteins that are 871 
statistically enriched in gp83-GFP immunoprecipitated (IP). The log2 LFQ intensity of gp83-GFP IP 872 
over control IP (cells that do not express gp83-GFP) is plotted against the -log10 FDR. The gp83-GFP 873 
bait (labelled in green) and interactors with an enrichment of fold change > 2.5; -log10 FDR > 1 are 874 
indicated. (B) Drs-FLuc expression was measured following co-transfection of pAc-gp83, pAc-TollLRR, 875 
or empty control plasmids, along with dsRNA targeting brf, msr-110, Nipped-B, RhoGEF2, spatzle, 876 
and Ulp1 (labelled red in panel A), with dsRNA targeting GFP as a control. Genes are superscripted 877 
with ‘1’ or ‘2’ when two independent dsRNAs were used to knock down the gene. Although msr-110 878 
kncockdown appears to partially rescue gp83 immunosuppression, subsequent experiments did not 879 
reproduce this effect. Error bars represent standard error of the mean (n=3). Statistical tests were 880 
performed in MCMCglmm. (C) V5-tagged gp83 or V5-tagged cact (an IκB protein known to interact 881 
with dl) were expressed alongside GFP-tagged dl or GFP and GFP-associated complexes were 882 
immunoprecipitated (IP) with GFP-trap magnetic beads and analyzed by western blot using V5 883 
antibodies. Note, cact appears to be stabilized when co-expressed with dl compared to when it is 884 




Figure 7: Overexpression of gp83 may reduce dorsal levels  887 
(A) Western blots show endogenous dl protein levels in S2 cells transfected with a plasmid encoding 888 
gp83 or empty control plasmid (left panel) and in S2 cells infected with KV (4 dpi) (right panel). The 889 
Toll pathway was activated by expression of pAc-TollLRR, as indicated. Western blot analysis using 890 
anti-Tubulin antibody was used to very equal loading.  . (B-C) The effect of gp83 was analyzed by 891 
confocal microscopy of S2 cells transfected with plasmid encoding gp83 or control plasmid, and 892 
plasmids encoding either GFP or dl-GFP. ImageJ-based quantification of mean GFP fluorescence for 893 
individually outlined cells (n ≥ 20 cells for each condition, error bars show standard error of the 894 
mean). (C) A representative image from (B), showing GFP (top panels) and dl-GFP expression (lower 895 




Figure 8: The immunosuppressive function of gp83 is evolutionarily conserved 898 
(A) Maximum likelihood phylogeny inferred from a protein alignment of nudivirus-encoded DNA 899 
polymerase B using PhyML (83), with an LG substitution model and gamma-distributed rate 900 
parameter. Support for each node was assessed by bootstrapping, and the scale bar represents 901 
substitutions per site. Nudivirus species that encode gp83 homologs are coloured in red. (B) 902 
Conservation of the gp83 amino acid sequence across 7 species of nudivirus (all red labelled viruses 903 
in panel A, except the endogenized virus NlENV). Each bar represents an amino acid, and bars are 904 
coloured yellow if the residue is conserved in ≥ 50% of the species, green if conserved in 100% of the 905 
species., and black if conserved in <50% of the species. Two V5-tagged gp83 constructs were created 906 
with deletionsthat span regions with an excess of conserved residues: gp83Δ1 and gp83Δ2. Western 907 
blot and subsequent V5 antibody staining show that both deletion constructs accumulate to similar 908 
levels as full-length gp83 following transfection of S2 cells. (C) Full-length gp83, gp83Δ1, or gp83Δ2 909 
were co-expressed with TollLRR, and Drs-FLuc expression was measured relative to pAct-FLuc 910 
expression. (D) V5-tagged gp83 from KV and DiNV were co-expressed with TollLRR to assess 911 
suppression of Drs-FLuc expression (relative to pAct-FLuc expression) in D. melanogaster S2 cells. 912 
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Western blot analyses using  V5 antibody was usedto confirm gp83 expression. Error bars show 913 
standard error of the mean (n = 5 biological replicates). *p < 0.05; **p < 0.01; ***p < 0.001 914 
(Statistical tests performed in MCMCglmm). 915 
 916 
